{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T23:34:22Z","timestamp":1781825662382,"version":"3.54.5"},"reference-count":22,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.jacl.2022.03.004","type":"journal-article","created":{"date-parts":[[2022,3,19]],"date-time":"2022-03-19T03:14:20Z","timestamp":1647659660000},"page":"315-324","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Exploring rates of PCSK9 inhibitor persistence and reasons for treatment non-persistence in an integrated specialty pharmacy model"],"prefix":"10.1016","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2646-341X","authenticated-orcid":false,"given":"Dustin R.","family":"Donald","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5300-4617","authenticated-orcid":false,"given":"Victoria W.","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8171-5766","authenticated-orcid":false,"given":"Josh","family":"DeClercq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leena","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.jacl.2022.03.004_bib0001","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2022.03.004_bib0002","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2022.03.004_bib0003","unstructured":"Repatha [package insert]. Amgen Inc., Thousand Oaks, CA. 2021.4.4."},{"key":"10.1016\/j.jacl.2022.03.004_bib0004","series-title":"Bridgewater, NJ: Sanofi-Aventis U.S. LLC\/Tarrytown","year":"2021"},{"issue":"5","key":"10.1016\/j.jacl.2022.03.004_bib0005","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.jacl.2019.06.008","article-title":"The patient journey with proprotein convertase subtilisin\/kexin type 9 inhibitors in community practice","volume":"13","author":"Bradley","year":"2019","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2022.03.004_sbref0006","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2147\/VHRM.S180496","article-title":"Treatment patterns and patient characteristics among early initiators of PCSK9 inhibitors","volume":"14","author":"Hines","year":"2018","journal-title":"Vasc Health Risk Manag"},{"issue":"8","key":"10.1016\/j.jacl.2022.03.004_bib0007","first-page":"815","article-title":"Advancing patient care through specialty pharmacy services in an academic health system","volume":"23","author":"Bagwell","year":"2017","journal-title":"J Manag Care Spec Pharm"},{"issue":"12","key":"10.1016\/j.jacl.2022.03.004_sbref0008","first-page":"1227","article-title":"Impact of specialty pharmacy on telaprevir-containing 3-drug hepatitis C regimen persistence","volume":"20","author":"Henderson","year":"2014","journal-title":"J Manag Care Spec Pharm"},{"issue":"7","key":"10.1016\/j.jacl.2022.03.004_sbref0009","first-page":"882","article-title":"Adherence and persistence in patients with rheumatoid arthritis at an integrated health system specialty pharmacy","volume":"27","author":"Peter","year":"2021","journal-title":"J Manag Care Spec Pharm"},{"issue":"2","key":"10.1016\/j.jacl.2022.03.004_bib0010","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.jacl.2019.01.003","article-title":"Integrated specialty pharmacy yields high pcsk9 inhibitor access and initiation rates","volume":"13","author":"Reynolds","year":"2019","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2022.03.004_bib0011","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap) - a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"issue":"24","key":"10.1016\/j.jacl.2022.03.004_bib0012","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.jacl.2022.03.004_bib0013","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1001\/jamacardio.2017.0747","article-title":"Long-term low-density lipoprotein cholesterol\u2013lowering efficacy, persistence, and safety of evolocumab in treatment of hypercholesterolemia: results up to 4 years from the open-label OSLER-1 extension study","volume":"2","author":"Koren","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacl.2022.03.004_bib0014","doi-asserted-by":"crossref","first-page":"957","DOI":"10.2147\/TCRM.S143008","article-title":"Real-world use of PCSK-9 inhibitors by early adopters: cardiovascular risk factors, statin co-treatment, and short-term adherence in routine clinical practice","volume":"13","author":"Fairman","year":"2017","journal-title":"Ther Clin Risk Manag"},{"issue":"4","key":"10.1016\/j.jacl.2022.03.004_sbref0015","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3390\/pharmacy7040163","article-title":"An integrated health-system specialty pharmacy model for coordinating transitions of care: specialty medication challenges and specialty pharmacist opportunities","volume":"7","author":"Zuckerman","year":"2019","journal-title":"Pharmacy (Basel)"},{"issue":"3","key":"10.1016\/j.jacl.2022.03.004_bib0016","first-page":"229","article-title":"The emergence of specialty pharmacy","volume":"26","author":"Vanscoy","year":"2020","journal-title":"J Manag Care Spec Pharm"},{"issue":"1","key":"10.1016\/j.jacl.2022.03.004_bib0017","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1161\/CIRCRESAHA.118.314191","article-title":"Application of PCSK9 inhibitors in practice","volume":"124","author":"Kaufman","year":"2019","journal-title":"Circ Res"},{"issue":"8","key":"10.1016\/j.jacl.2022.03.004_bib0018","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.118.005404","article-title":"Effect of access to prescribed PCSK9 inhibitors on cardiovascular outcomes","volume":"12","author":"Myers","year":"2019","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"7","key":"10.1016\/j.jacl.2022.03.004_sbref0019","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1001\/jamacardio.2019.1647","article-title":"Updated cost-effectiveness analysis of evolocumab in patients with very high-risk atherosclerotic cardiovascular disease","volume":"4","author":"Fonarow","year":"2019","journal-title":"JAMA Cardiol"},{"issue":"18","key":"10.1016\/j.jacl.2022.03.004_sbref0020","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1016\/j.jacc.2020.03.029","article-title":"Cost-effectiveness of alirocumab in patients with acute coronary syndromes: the odyssey outcomes trial","volume":"75","author":"Bhatt","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.jacl.2022.03.004_sbref0021","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jacl.2021.01.010","article-title":"Characteristics and trends of PCSK9 inhibitor prescription fills in the United States","volume":"15","author":"Attipoe-Dorcoo","year":"2021","journal-title":"J Clin Lipidol"},{"issue":"1","key":"10.1016\/j.jacl.2022.03.004_sbref0022","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1200\/JOP.2016.012302","article-title":"Potential obstacles in the acquisition of oral anticancer medications","volume":"13","author":"Niccolai","year":"2017","journal-title":"J Oncol Pract"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S193328742200037X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S193328742200037X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T13:36:59Z","timestamp":1761831419000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S193328742200037X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S193328742200037X"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2022.03.004","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploring rates of PCSK9 inhibitor persistence and reasons for treatment non-persistence in an integrated specialty pharmacy model","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2022.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 National Lipid Association. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}